| | | 00612 | | 18.08.1999 | | Sanofi-Aventis (Suisse) SA | | | | | | | | | | | | | 08.08. | | | | 08.08. | | FI |
| | Seq.-Nr. | Präparat | Beschreibung | Galenische Form | ATC-Klassierung | |
|---|
| 01 | Tetravac | suspension injectable | Injektionssuspension (Toxoidum Diphtheriae 20 UI, Toxoidum Tetani 40 UI) | J07CA02 | | | 02 | Tetravac | | (Virus Poliomyelitis Typus 1 Inactivatum (Mahoney) 40 U, Virus Poliomyelitis Typus 2 Inactivatum (Mef1) 8 U, Virus Poliomyelitis Typus 3 Inactivatum (Saukett) 32 U, Toxoidum Diphtheriae 20 UI, Toxoidum Tetani 40 UI, Toxoidum Pertussis 25 mcg) | Codice | | | 03 | Tetravac | | (Toxoidum Diphtheriae 20 UI, Toxoidum Tetani 40 UI, Toxoidum Pertussis 25 mcg, Vaccinum Poliomyelitidis Inactivatum (Salk typ I, II, III) 62 U) | | |
|
|
